Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.67 |
| ▸ | GSK3A | P49840 | 8/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.67 |
| ▸ | CLK2 | P49760 | 7/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 6/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.67 |
| ▸ | KDR | P35968 | 6/20 | 0.67 |
| ▸ | STK17A | Q9UEE5 | 6/20 | 0.67 |
| ▸ | CDK2 | P24941 | 5/20 | 0.67 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.67 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.67 |
| ▸ | FLT4 | P35916 | 4/20 | 0.67 |
| ▸ | BRSK1 | Q8TDC3 | 4/20 | 0.67 |
| ▸ | SGK2 | Q9HBY8 | 3/20 | 0.67 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.67 |
| ▸ | PLK4 | O00444 | 2/20 | 0.67 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10296674 | 0.84 | CLK4 (0.71) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL3802577 | 0.83 | CLK4 (0.70) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL1421498 | 0.83 | CLK4 (0.70) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL10008353 | 0.81 | CLK2 (0.70) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL3802860 | 0.81 | CLK4 (1.00) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL31061009 | 0.80 | GSK3B (1.00) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL3795310 | 0.80 | GSK3B (1.00) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL4561276 | 0.78 | CLK4 (0.62) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL10296639 | 0.76 | CLK4 (0.83) | GSK3BCLK4GSK3ACDK5CLK2 | |
| SCHEMBL1421049 | 0.76 | GSK3B (0.70) | GSK3BCLK4GSK3ACDK5CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540370-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20150274724-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-01 | — | — | US | disclosed |
| US-9090592-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-07-28 | — | — | US | disclosed |
| WO-2012089828-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-07-05 | — | — | WO | disclosed |
| US-20120172376-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274724-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | GSK3B 1/4885CLK4 1296/4885GSK3A 2/4885 |
| US-20120172376-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | GSK3B 1/4885CLK4 1296/4885GSK3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.